Comparable stake leader
Cedars Sinai Intellectual Property Co
SEC ownership of Prometheus Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001718852.
Disclosed value leader
Cedars Sinai Intellectual Property Co
Comparable rows
0/3
Latest evidence
08 Mar 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Cedars Sinai Intellectual Property Co
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
08 Mar 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001718852
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Prometheus Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cedars Sinai Intellectual...
Disclosed value leader
Cedars Sinai Intellectual...
Comparable rows
0/3
Latest evidence
08 Mar 2023
3/4/5
Highest disclosed value: $433,802,731
3 rows are not safely comparable across share classes.
Quick read
Cedars Sinai Intellectual Property Co has the largest disclosed position value at $433.8M.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Cedars Sinai Intellectual Property Co's linked filing trail.
Disclosed position value
Top 1
Cedars Sinai Intellectual Propert...
$433.8M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cedars Sinai Intellectual Property Co |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$433,802,731
4,001,132 shares
|
— | 08 Mar 2023 |
| Allison Luo |
3/4/5
Chief Medical Officer
|
—
class O/S missing
|
—
113,677 shares
|
— | 14 Nov 2021 |
| Timothy K. Andrews |
3/4/5
General Counsel
|
—
class O/S missing
|
—
54,132 shares
|
— | 14 Nov 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to Prometheus Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Cedars Sinai Intellectual Property Co
Net 12M change
$0
Latest report
16 Jun 2023
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Cedars Sinai Intellectual Property Co | 10%+ Owner | $433,802,731 | Mixed | 08 Mar 2023 | ||
| Fred Hassan | Director | Mixed | 16 Jun 2023 | |||
| Helen C. Adams | Director | Mixed | 16 Jun 2023 | |||
| Timothy K. Andrews | General Counsel | Mixed | 14 Nov 2021 | |||
| Keith W. Marshall | Chief Financial Officer | Mixed | 16 Jun 2023 | |||
| Allison Luo | Chief Medical Officer | Mixed | 14 Nov 2021 | |||
| Joseph C. Papa | Director | Mixed | 16 Jun 2023 | |||
| Mark C. McKenna | Chairman, President and CEO, Director | Mixed | 16 Jun 2023 | |||
| Mark Stenhouse | Chief Operating Officer | Mixed | 16 Jun 2023 | |||
| James Laur | Director | Mixed | 16 Jun 2023 | |||
| Martin Hendrix | Director | Mixed | 16 Jun 2023 | |||
| Judith L. Swain | Director | Mixed | 16 Jun 2023 | |||
| Szela Mary T. | Director | Mixed | 16 Jun 2023 |
Recent insider transactions for Prometheus Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.